> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Endari Updated Prescribing Info
- URL: https://www.fdaweb.com/fda-oks-endari-updated-prescribing-info/
- Published: 2020-11-03T12:00:00.000Z
- Updated: 2026-09-14T16:34:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148011

FDA has approved updated prescribing information for Emmaus Life Sciences’ Endari (L-glutamine oral powder) to better inform healthcare professionals and sickle cell disease patients. The updated label includes a statement that the clinical benefit of Endari was observed irrespective of hydroxyurea usage and a new step-by-step instructions for use section at the end of the prescribing information. Endari was approved by the agency 7/2017 for treating sickle cell disease by reducing acute complications in adult and pediatric patients five years of age and older.